Wolfgang Muecke: search on Z-Library

The world's largest scientific articles store. 70,000,000+ articles for free.

Don't use scam websites

1

Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban-an Oral, Direct Factor Xa Inhibitor-Are Not Affected by Aspirin

Kubitza, Dagmar, Becka, Michael, Mueck, Wolfgang, Zuehlsdorf, Michael

Journal:

Journal of Clinical Pharmacology

Year:

2006

Language:

english

File:

PDF, 139 KB

english, 2006

2

Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban — an Oral, Direct Factor Xa Inhibitor — in Patients Undergoing Major Orthopaedic Surgery

Dr Wolfgang Mueck, Bengt I. Eriksson, Kenneth A. Bauer, Lars Borris, Ola E. Dahl, William D. Fisher, Michael Gent, Sylvia Haas, Menno V. Huisman, Ajay K. Kakkar, Peter Kälebo, Louis M. Kwong, Frank Mi

Journal:

Clinical Pharmacokinetics

Year:

2008

Language:

english

File:

PDF, 693 KB

english, 2008

3

Rivaroxaban

Dr Wolfgang Mueck, Anthonie W. A. Lensing, Giancarlo Agnelli, Hervé Décousus, Paolo Prandoni, Frank Misselwitz

Journal:

Clinical Pharmacokinetics

Year:

2011

Language:

english

File:

PDF, 493 KB

english, 2011

4

Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring

Wolfgang Mueck, Stephan Schwers, Jan Stampfuss

Journal:

Thrombosis Journal

Year:

2013

Language:

english

File:

PDF, 456 KB

english, 2013

5

Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban

Mueck, Wolfgang, Stampfuss, Jan, Kubitza, Dagmar, Becka, Michael

Journal:

Clinical Pharmacokinetics

Year:

2014

Language:

english

File:

PDF, 636 KB

english, 2014

6

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

Kubitza, Dagmar, Becka, Michael, Roth, Angelika, Mueck, Wolfgang

Journal:

Current Medical Research and Opinion

Year:

2008

Language:

english

File:

PDF, 267 KB

english, 2008

7

Effect of Food, an Antacid, and the H 2 Antagonist Ranitidine on the Absorption of BAY 59-7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects

Kubitza, Dagmar, Becka, Michael, Zuehlsdorf, Michael, Mueck, Wolfgang

Journal:

Journal of Clinical Pharmacology

Year:

2006

Language:

english

File:

PDF, 106 KB

english, 2006

8

Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects

Boettcher, Michael, Thomas, Dirk, Mueck, Wolfgang, Loewen, Stephanie, Arens, Erich, Yoshikawa, Kenichi, Becker, Corina

Journal:

European Journal of Clinical Pharmacology

Year:

2020

File:

PDF, 484 KB

2020

9

Antiplatelet effects of aspirin are not affected by the soluble guanylate cyclase activator cinaciguat (BAY 58-2667)

Reiner Frey, Wolfgang Mueck, Michael Becka, Joern Kraetzschmar, Georg Wensing

Journal:

BMC Pharmacology

Year:

2011

Language:

english

File:

PDF, 138 KB

english, 2011

10

Pharmacokinetic analysis of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in individuals with renal impairment compared to healthy controls

Christian Scheerans, Martin Blunck, Wolfgang Mueck, Reiner Frey

Journal:

BMC Pharmacology

Year:

2011

Language:

english

File:

PDF, 142 KB

english, 2011

11

Keratocyte density in the retroablation area after LASEK for the correction of myopia

Wolfgang Artur Herrmann, Manuela Muecke, Michael Koller, Veit Peter Gabel, Chris Patrick Lohmann

Journal:

Graefe's Archive for Clinical and Experimental Ophthalmology

Year:

2007

Language:

english

File:

PDF, 127 KB

english, 2007

12

Austrian Moderate Altitude Studies (AMAS): benefits of exposure to moderate altitudes (1,500–2,500

Wolfgang Schobersberger, Veronika Leichtfried, Michael Mueck-Weymann, Egon Humpeler

Journal:

Sleep and Breathing

Year:

2010

Language:

english

File:

PDF, 151 KB

english, 2010

13

Rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen

Dagmar Kubitza, Michael Becka, Wolfgang Mueck, Michael Zuehlsdorf

Journal:

British Journal of Clinical Pharmacology

Year:

2007

Language:

english

File:

PDF, 173 KB

english, 2007

14

Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects

Xia Zhao, Peihong Sun, Ying Zhou, Yuwang Liu, Huilin Zhang, Wolfgang Mueck, Dagmar Kubitza, Richard J. Bauer, Hong Zhang, Yimin Cui

Journal:

British Journal of Clinical Pharmacology

Year:

2009

Language:

english

File:

PDF, 1.04 MB

english, 2009

15

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

Dagmar Kubitza, Michael Becka, Wolfgang Mueck, Atef Halabi, Haidar Maatouk, Norbert Klause, Volkmar Lufft, Dominic D. Wand, Thomas Philipp, Heike Bruck

Journal:

British Journal of Clinical Pharmacology

Year:

2010

Language:

english

File:

PDF, 1.33 MB

english, 2010

16

Species differences in the toxicity of p-chloro-o-toluidine to rats and mice. Covalent binding to hepatic macromolecules and hepatic non-parenchymal cell DNA and an investigation of effects upon the incorporation of [3H] thymidine into capillary endothelial cells

Philip Bentley, Francoise Bieri, Wolfgang Muecke, Felix Waechter, Willy Stäubli

Journal:

Chemico-Biological Interactions

Year:

1986

File:

PDF, 787 KB

1986

17

Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes

Xu Steven Xu, Kenneth Moore, Paul Burton, Kim Stuyckens, Wolfgang Mueck, Stefaan Rossenu, Alexei Plotnikov, Michael Gibson, An Vermeulen

Journal:

British Journal of Clinical Pharmacology

Year:

2012

Language:

english

File:

PDF, 1.69 MB

english, 2012

18

Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor

Kubitza, Dagmar, Roth, Angelika, Becka, Michael, Alatrach, Abir, Halabi, Atef, Hinrichsen, Holger, Mueck, Wolfgang

Journal:

British Journal of Clinical Pharmacology

Year:

2013

Language:

english

File:

PDF, 435 KB

english, 2013

19

Dose-Related Hemodynamic and Electrocardiographic Effects of the Calcium Promoter BAY y 5959 in the Presence or Absence of Congestive Heart Failure

Michel F Rousseau, Pierre-E Massart, Christian van Eyll, Jean Etienne, Sylvie Ahn, Hans G Schaefer, Wolfgang Mueck, Martin Bornemann, Hubert Pouleur

Journal:

Journal of the American College of Cardiology

Year:

1997

Language:

english

File:

PDF, 166 KB

english, 1997

20

Randomized, Double-Blind, Crossover Study to Investigate the Effect of Rivaroxaban on QT-Interval Prolongation

Dr Dagmar Kubitza, Wolfgang Mueck, Michael Becka

Journal:

Year:

2008

Language:

english

File:

PDF, 145 KB

english, 2008

21

Population Pharmacokinetics and Pharmacodynamics of Cinaciguat, a Soluble Guanylate Cyclase Activator, in Patients with Acute Decompensated Heart Failure

Dr Wolfgang Mueck, Reiner Frey

Journal:

Clinical Pharmacokinetics

Year:

2010

Language:

english

File:

PDF, 251 KB

english, 2010

22

Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects

Mueck, Wolfgang, Kubitza, Dagmar, Becka, Michael

Journal:

British Journal of Clinical Pharmacology

Year:

2013

Language:

english

File:

PDF, 516 KB

english, 2013

23

Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber

Wolzt, Michael, Gouya, Ghazaleh, Kapiotis, Stylianos, Becka, Michael, Mueck, Wolfgang, Kubitza, Dagmar

Journal:

Thrombosis Research

Year:

2013

Language:

english

File:

PDF, 438 KB

english, 2013

24

Pharmacokinetic interaction of ketoconazole, clarithromycin, and midazolam with riociguat

Becker, Corina, Frey, Reiner, Unger, Sigrun, Thomas, Dirk, Reber, Michael, Weimann, Gerrit, Dietrich, Hartmut, Arens, Erich R, Mueck, Wolfgang

Journal:

BMC Pharmacology and Toxicology

Year:

2013

Language:

english

File:

PDF, 438 KB

english, 2013

25

Absorption behavior of riociguat: bioavailability, food effects, and dose-proportionality

Becker, Corina, Frey, Reiner, Hesse, Christiane, Unger, Sigrun, Reber, Michael, Mueck, Wolfgang

Journal:

BMC Pharmacology and Toxicology

Year:

2013

Language:

english

File:

PDF, 341 KB

english, 2013

26

Effects of omeprazole and AlOH/MgOH on riociguat absorption

Becker, Corina, Frey, Reiner, Unger, Sigrun, Artmeier-Brandt, Ulrike, Weimann, Gerrit, Mueck, Wolfgang

Journal:

BMC Pharmacology and Toxicology

Year:

2013

Language:

english

File:

PDF, 290 KB

english, 2013

27

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment

Frey, Reiner, Becker, Corina, Unger, Sigrun, Schmidt, Anja, Wensing, Georg, Mueck, Wolfgang

Journal:

BMC Pharmacology and Toxicology

Year:

2013

Language:

english

File:

PDF, 168 KB

english, 2013

28

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment

Frey, Reiner, Becker, Corina, Unger, Sigrun, Schmidt, Anja, Wensing, Georg, Mueck, Wolfgang

Journal:

BMC Pharmacology and Toxicology

Year:

2013

Language:

english

File:

PDF, 203 KB

english, 2013

29

Real-time reaction monitoring by continuous-introduction ion-spray tandem mass spectrometry

Lee, Edgar D., Mueck, Wolfgang, Henion, Jack D., Covey, Thomas R.

Journal:

Journal of the American Chemical Society

Year:

1989

Language:

english

File:

PDF, 607 KB

english, 1989

30

Degradation of carbon-14 labeled diazinon in the rat

Muecke, Wolfgang., Alt, K. O., Esser, Herbert E.

Journal:

Journal of Agricultural and Food Chemistry

Year:

1970

Language:

english

File:

PDF, 491 KB

english, 1970

31

A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma – long-term results of a multicenter observation study

Weigert, Oliver, Weidmann, Eckhart, Mueck, Rudolf, Bentz, Martin, von Schilling, Christoph, Rohrberg, Robert, Jentsch-Ullrich, Kathleen, Hiddemann, Wolfgang, Dreyling, Martin

Journal:

Leukemia and Lymphoma

Year:

2009

Language:

english

File:

PDF, 227 KB

english, 2009

32

The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor

Kubitza, Dagmar, Becka, Michael, Roth, Angelika, Mueck, Wolfgang

Journal:

Journal of Clinical Pharmacology

Year:

2013

Language:

english

File:

PDF, 266 KB

english, 2013

33

Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59-7939) in Healthy Subjects

Kubitza, Dagmar, Becka, Michael, Zuehlsdorf, Michael, Mueck, Wolfgang

Journal:

Journal of Clinical Pharmacology

Year:

2007

Language:

english

File:

PDF, 431 KB

english, 2007

34

Proposal for defining the relevance of drug accumulation derived from single dose study data for modified release dosage forms

Scheerans, Christian, Heinig, Roland, Mueck, Wolfgang

Journal:

Biopharmaceutics & Drug Disposition

Year:

2015

Language:

english

File:

PDF, 227 KB

english, 2015

35

Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease

Ghofrani, Hossein A., Staehler, Gerd, Grünig, Ekkehard, Halank, Michael, Mitrovic, Veselin, Unger, Sigrun, Mueck, Wolfgang, Frey, Reiner, Grimminger, Friedrich, Schermuly, Ralph T., Behr, Juergen

Journal:

Pulmonary Circulation

Year:

2015

Language:

english

File:

PDF, 279 KB

english, 2015

36

Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxabanâ€”an oral, direct Factor Xa inhibitor

Burghaus, Rolf, Coboeken, Katrin, Gaub, Thomas, Niederalt, Christoph, Sensse, Anke, Siegmund, Hans-Ulrich, Weiss, Wolfgang, Mueck, Wolfgang, Tanigawa, Takahiko, Lippert, JÃ¶rg

Journal:

Frontiers in Physiology

Year:

2014

Language:

english

File:

PDF, 4.96 MB

english, 2014

37

[American Thoracic Society American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado - ()] D96. CLINICAL TRIALS AND OUTCOMES IN PULMONARY HYPERTENSION - The Effect Of The Soluble Guanylate Cyclase Stimulator Riociguat On Hemodynamics In Patients With Pulmonary Hypertension Due To Chronic Obstructive Pulmonary Disease

Ghofrani, Hossein-Ardeschir, Staehler, Gerd, Gruenig, Ekkehard, Halank, Michael, Mitrovic, Veselin, Unger, Sigrun, Mueck, Wolfgang, Frey, Reiner, Behr, Juergen

Year:

2011

Language:

english

File:

PDF, 18 KB

english, 2011

38

Predicting biopharmaceutical performance of oral drug candidates – Extending the volume to dissolve applied dose concept

Muenster, Uwe, Mueck, Wolfgang, van der Mey, Dorina, Schlemmer, Karl-Heinz, Greschat-Schade, Susanne, Haerter, Michael, Pelzetter, Christian, Pruemper, Christian, Verlage, Joerg, Göller, Andreas H., O

Journal:

European Journal of Pharmaceutics and Biopharmaceutics

Year:

2016

Language:

english

File:

PDF, 1.55 MB

english, 2016

39

Can dosage form-dependent food effects be predicted using biorelevant dissolution tests? Case example extended release nifedipine

Andreas, Cord J., Tomaszewska, Irena, Muenster, Uwe, van der Mey, Dorina, Mueck, Wolfgang, Dressman, Jennifer B.

Journal:

European Journal of Pharmaceutics and Biopharmaceutics

Year:

2016

Language:

english

File:

PDF, 1.92 MB

english, 2016

40

Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.

Mueck, Wolfgang, Borris, Lars C, Dahl, Ola E, Haas, Sylvia, Huisman, Menno V, Kakkar, Ajay K, Kalebo, Peter, Muelhofer, Eva, Misselwitz, Frank, Eriksson, Bengt I

Journal:

Thrombosis and Haemostasis

Year:

2008

Language:

english

File:

PDF, 2.28 MB

english, 2008

41

Model-based Dose Selection for Phase III Rivaroxaban Study in Japanese Patients with Non-valvular Atrial Fibrillation

Tanigawa, Takahiko, Kaneko, Masato, Hashizume, Kensei, Kajikawa, Mariko, Ueda, Hitoshi, Tajiri, Masahiro, Paolini, John F., Mueck, Wolfgang

Journal:

Drug Metabolism and Pharmacokinetics

Year:

2013

Language:

english

File:

PDF, 2.04 MB

english, 2013

42

Confirmation of Model-based Dose Selection for a Japanese Phase III Study of Rivaroxaban in Non-valvular Atrial Fibrillation Patients

Kaneko, Masato, Tanigawa, Takahiko, Hashizume, Kensei, Kajikawa, Mariko, Tajiri, Masahiro, Mueck, Wolfgang

Journal:

Drug Metabolism and Pharmacokinetics

Year:

2013

Language:

english

File:

PDF, 1.93 MB

english, 2013

43

Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations

Willmann, Stefan, Zhang, Liping, Frede, Matthias, Kubitza, Dagmar, Mueck, Wolfgang, Schmidt, Stephan, Solms, Alexander, Yan, Xiaoyu, Garmann, Dirk

Journal:

CPT: Pharmacometrics & Systems Pharmacology

Year:

2018

Language:

english

File:

PDF, 607 KB

english, 2018

44

Evaluation of the Efficacy and Safety of Rivaroxaban Using a Computer Model for Blood Coagulation

Burghaus, Rolf, Coboeken, Katrin, Gaub, Thomas, Kuepfer, Lars, Sensse, Anke, Siegmund, Hans-Ulrich, Weiss, Wolfgang, Mueck, Wolfgang, Lippert, Joerg, Uversky, Vladimir N.

Journal:

Year:

2011

Language:

english

File:

PDF, 1.15 MB

english, 2011

45

A Comprehensive Comparison of the Efficacy and Tolerability of Racecadotril with Other Treatments of Acute Diarrhea in Adults

Fischbach, Wolfgang, Andresen, Viola, Eberlin, Marion, Mueck, Tobias, Layer, Peter

Journal:

Frontiers in Medicine

Year:

2016

Language:

english

File:

PDF, 661 KB

english, 2016

46

Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban – an oral, direct factor Xa inhibitor – in elderly Chinese subjects

Jiang, Ji, Hu, Yufang, Zhang, Jianyan, Yang, Jueling, Mueck, Wolfgang, Kubitza, Dagmar, Bauer, Richard, Meng, Ling, Hu, Pei

Journal:

Thrombosis and Haemostasis

Year:

2010

Language:

english

File:

PDF, 627 KB

english, 2010

47

EXPRESS: Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults

DeJesus, Edwin, Saleh, Soundos, Cheng, Sue, van der Mey, Dorina, Becker, Corina, Frey, Reiner, Unger, Sigrun, Mueck, Wolfgang

Journal:

Pulmonary Circulation

Year:

2019

Language:

english

File:

PDF, 749 KB

english, 2019

48

Inhibition of Ergosterol Biosynthesis by Etaconazole in Ustilago maydis

Ebert, Edith, Gaudin, John, Muecke, Wolfgang, Ramsteiner, Klaus, Vogel, Christian, Führer, Hermann

Journal:

Zeitschrift für Naturforschung C

Year:

1983

Language:

english

File:

PDF, 5.65 MB

english, 1983

49

Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling

Solms, Alexander, Frede, Matthias, Berkowitz, Scott D., Hermanowski‐Vosatka, Anne, Kubitza, Dagmar, Mueck, Wolfgang, Spiro, Theodore E., Willmann, Stefan, Yan, Xiaoyu, Zhang, Liping, Garmann, Dirk

Journal:

CPT: Pharmacometrics & Systems Pharmacology

Year:

2019

Language:

english

File:

PDF, 9.22 MB

english, 2019

50

Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement

Mueck, Wolfgang, Borris, Lars C., Dahl, Ola E., Haas, Sylvia, Huisman, Menno V., Kakkar, Ajay K., Kälebo, Peter, Muelhofer, Eva, Misselwitz, Frank, Eriksson, Bengt I.

Journal:

Thrombosis and Haemostasis

Year:

2008

Language:

english

File:

PDF, 1.62 MB

english, 2008